aminopyrazole based JNK 2/3 inhibitors (Scripps Research Institute)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameaminopyrazole based JNK 2/3 inhibitors (Scripps Research Institute)
Drug Alias NameJun N terminal kinase inhibitors (Scripps Research Institute)Tat-SabKIM1
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of Actionc-Jun N-terminal kinase 2 inhibitorsc-Jun N-terminal kinase 3 inhibitors
Targetsc-Jun N-terminal kinase 2c-Jun N-terminal kinase 3
Therapy Area/IndicationsMyocardial Reperfusion InjuryAmyotrophic Lateral SclerosisParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe Scripps Research Institute Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe Scripps Research Institute Inc
Active IndicationsN/A
Inactive IndicationsMyocardial Reperfusion InjuryAmyotrophic Lateral SclerosisParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A